{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T07:52:06Z","timestamp":1768809126633,"version":"3.49.0"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T00:00:00Z","timestamp":1636588800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T00:00:00Z","timestamp":1636588800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Conjugate vaccine platform is a promising strategy to overcome the poor immunogenicity of bacterial polysaccharide antigens in infants and children. A carrier protein in conjugate vaccines works not only as an immune stimulator to polysaccharide, but also as an immunogen; with the latter generally not considered as a measured outcome in real world. Here, we probed the potential of a conjugate vaccine platform to induce enhanced immunogenicity of a truncated rotavirus spike protein \u0394VP8*. \u0394VP8* was covalently conjugated to Vi capsular polysaccharide (Vi) of <jats:italic>Salmonella<\/jats:italic> Typhi to develop a bivalent vaccine, termed Vi-\u0394VP8*. Our results demonstrated that the Vi-\u0394VP8* vaccine can induce specific immune responses against both antigens in immunized mice. The conjugate vaccine elicits high antibody titers and functional antibodies against <jats:italic>S<\/jats:italic>. Typhi and Rotavirus (RV) when compared to immunization with a single antigen. Together, these results indicate that Vi-\u0394VP8* is a potent and immunogenic vaccine candidate, thus strengthening the potential of conjugate vaccine platform with enhanced immune responses to carrier protein, including \u0394VP8*.<\/jats:p>","DOI":"10.1038\/s41598-021-01549-z","type":"journal-article","created":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T11:06:09Z","timestamp":1636628769000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Rotavirus spike protein \u0394VP8* as a novel carrier protein for conjugate vaccine platform with demonstrated antigenic potential for use as bivalent vaccine"],"prefix":"10.1038","volume":"11","author":[{"given":"Wook-Jin","family":"Park","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yeon-Kyung","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji-Sun","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruchirkumar","family":"Pansuriya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yeong-Jae","family":"Seok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravi","family":"Ganapathy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,11]]},"reference":[{"key":"1549_CR1","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/S1473-3099(11)70253-5","volume":"12","author":"JE Tate","year":"2012","unstructured":"Tate, J. E. et al. 2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: A systematic review and meta-analysis. Lancet Infect. Dis. 12, 136\u2013141. https:\/\/doi.org\/10.1016\/S1473-3099(11)70253-5 (2012).","journal-title":"Lancet Infect. Dis."},{"key":"1549_CR2","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/S1473-3099(18)30362-1","volume":"18","author":"GBDDD Collaborators","year":"2018","unstructured":"Collaborators, G. B. D. D. D. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of diarrhoea in 195 countries: A systematic analysis for the Global Burden of Disease Study 2016. Lancet Infect. Dis. 18, 1211\u20131228. https:\/\/doi.org\/10.1016\/S1473-3099(18)30362-1 (2018).","journal-title":"Lancet Infect. Dis."},{"key":"1549_CR3","doi-asserted-by":"publisher","first-page":"304","DOI":"10.3201\/eid1202.050006","volume":"12","author":"UD Parashar","year":"2006","unstructured":"Parashar, U. D., Gibson, C. J., Bresee, J. S. & Glass, R. I. Rotavirus and severe childhood diarrhea. Emerg. Infect. Dis. 12, 304\u2013306. https:\/\/doi.org\/10.3201\/eid1202.050006 (2006).","journal-title":"Emerg. Infect. Dis."},{"key":"1549_CR4","unstructured":"WHO. Vaccine in national immunization programme update. (2020)."},{"key":"1549_CR5","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.4161\/hv.7.12.18321","volume":"7","author":"C Yen","year":"2011","unstructured":"Yen, C. et al. Rotavirus vaccines: Update on global impact and future priorities. Hum. Vaccin. 7, 1282\u20131290. https:\/\/doi.org\/10.4161\/hv.7.12.18321 (2011).","journal-title":"Hum. Vaccin."},{"key":"1549_CR6","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1093\/cid\/cix369","volume":"65","author":"CL Jonesteller","year":"2017","unstructured":"Jonesteller, C. L., Burnett, E., Yen, C., Tate, J. E. & Parashar, U. D. Effectiveness of rotavirus vaccination: A systematic review of the first decade of global postlicensure data, 2006\u20132016. Clin. Infect. Dis. 65, 840\u2013850. https:\/\/doi.org\/10.1093\/cid\/cix369 (2017).","journal-title":"Clin. Infect. Dis."},{"issue":"Suppl 2","key":"1549_CR7","doi-asserted-by":"publisher","first-page":"S29","DOI":"10.1016\/S1201-9712(07)60019-8","volume":"11","author":"T Vesikari","year":"2007","unstructured":"Vesikari, T. et al. Efficacy of a pentavalent rotavirus vaccine in reducing rotavirus-associated health care utilization across three regions (11 countries). Int. J. Infect. Dis. 11(Suppl 2), S29-35. https:\/\/doi.org\/10.1016\/S1201-9712(07)60019-8 (2007).","journal-title":"Int. J. Infect. Dis."},{"key":"1549_CR8","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/S0140-6736(10)60755-6","volume":"376","author":"K Zaman","year":"2010","unstructured":"Zaman, K. et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet 376, 615\u2013623. https:\/\/doi.org\/10.1016\/S0140-6736(10)60755-6 (2010).","journal-title":"Lancet"},{"key":"1549_CR9","first-page":"108","volume":"28","author":"SA Madhi","year":"2016","unstructured":"Madhi, S. A. et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. Malawi. Med. J. 28, 108\u2013114 (2016).","journal-title":"Malawi. Med. J."},{"key":"1549_CR10","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/S0140-6736(10)60889-6","volume":"376","author":"GE Armah","year":"2010","unstructured":"Armah, G. E. et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet 376, 606\u2013614. https:\/\/doi.org\/10.1016\/S0140-6736(10)60889-6 (2010).","journal-title":"Lancet"},{"key":"1549_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens6040065","author":"U Desselberger","year":"2017","unstructured":"Desselberger, U. Differences of rotavirus vaccine effectiveness by country: Likely causes and contributing factors. Pathogens https:\/\/doi.org\/10.3390\/pathogens6040065 (2017).","journal-title":"Pathogens"},{"key":"1549_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/emi.2017.30","volume":"6","author":"X Jiang","year":"2017","unstructured":"Jiang, X., Liu, Y. & Tan, M. Histo-blood group antigens as receptors for rotavirus, new understanding on rotavirus epidemiology and vaccine strategy. Emerg. Microbes Infect. 6, e22. https:\/\/doi.org\/10.1038\/emi.2017.30 (2017).","journal-title":"Emerg. Microbes Infect."},{"key":"1549_CR13","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1080\/21645515.2016.1197452","volume":"12","author":"C Yen","year":"2016","unstructured":"Yen, C. et al. Rotavirus vaccination and intussusception - Science, surveillance, and safety: A review of evidence and recommendations for future research priorities in low and middle income countries. Hum. Vaccin. Immunother. 12, 2580\u20132589. https:\/\/doi.org\/10.1080\/21645515.2016.1197452 (2016).","journal-title":"Hum. Vaccin. Immunother."},{"key":"1549_CR14","doi-asserted-by":"publisher","first-page":"7328","DOI":"10.1016\/j.vaccine.2017.03.076","volume":"37","author":"CD Kirkwood","year":"2019","unstructured":"Kirkwood, C. D., Ma, L. F., Carey, M. E. & Steele, A. D. The rotavirus vaccine development pipeline. Vaccine 37, 7328\u20137335. https:\/\/doi.org\/10.1016\/j.vaccine.2017.03.076 (2019).","journal-title":"Vaccine"},{"key":"1549_CR15","doi-asserted-by":"publisher","first-page":"6754","DOI":"10.1016\/j.vaccine.2008.10.008","volume":"26","author":"B Jiang","year":"2008","unstructured":"Jiang, B., Gentsch, J. R. & Glass, R. I. Inactivated rotavirus vaccines: a priority for accelerated vaccine development. Vaccine 26, 6754\u20136758. https:\/\/doi.org\/10.1016\/j.vaccine.2008.10.008 (2008).","journal-title":"Vaccine"},{"key":"1549_CR16","doi-asserted-by":"publisher","first-page":"25735","DOI":"10.1038\/srep25735","volume":"6","author":"M Xia","year":"2016","unstructured":"Xia, M. et al. Development and evaluation of two subunit vaccine candidates containing antigens of hepatitis E virus, rotavirus, and astrovirus. Sci. Rep. 6, 25735. https:\/\/doi.org\/10.1038\/srep25735 (2016).","journal-title":"Sci. Rep."},{"key":"1549_CR17","doi-asserted-by":"publisher","first-page":"6121","DOI":"10.1016\/j.vaccine.2012.07.078","volume":"30","author":"X Wen","year":"2012","unstructured":"Wen, X. et al. Construction and characterization of human rotavirus recombinant VP8* subunit parenteral vaccine candidates. Vaccine 30, 6121\u20136126. https:\/\/doi.org\/10.1016\/j.vaccine.2012.07.078 (2012).","journal-title":"Vaccine"},{"key":"1549_CR18","doi-asserted-by":"publisher","first-page":"8427","DOI":"10.1016\/j.biomaterials.2014.06.021","volume":"35","author":"L Wang","year":"2014","unstructured":"Wang, L. et al. Branched-linear and agglomerate protein polymers as vaccine platforms. Biomaterials 35, 8427\u20138438. https:\/\/doi.org\/10.1016\/j.biomaterials.2014.06.021 (2014).","journal-title":"Biomaterials"},{"key":"1549_CR19","doi-asserted-by":"publisher","first-page":"4480","DOI":"10.1016\/j.biomaterials.2013.02.041","volume":"34","author":"L Wang","year":"2013","unstructured":"Wang, L. et al. Polyvalent complexes for vaccine development. Biomaterials 34, 4480\u20134492. https:\/\/doi.org\/10.1016\/j.biomaterials.2013.02.041 (2013).","journal-title":"Biomaterials"},{"key":"1549_CR20","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1002\/eji.200425449","volume":"35","author":"M Nassal","year":"2005","unstructured":"Nassal, M. et al. A fusion product of the complete Borrelia burgdorferi outer surface protein A (OspA) and the hepatitis B virus capsid protein is highly immunogenic and induces protective immunity similar to that seen with an effective lipidated OspA vaccine formula. Eur. J. Immunol. 35, 655\u2013665. https:\/\/doi.org\/10.1002\/eji.200425449 (2005).","journal-title":"Eur. J. Immunol."},{"key":"1549_CR21","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/jmr.300060206","volume":"6","author":"PT Kaumaya","year":"1993","unstructured":"Kaumaya, P. T. et al. Peptide vaccines incorporating a \u201cpromiscuous\u201d T-cell epitope bypass certain haplotype restricted immune responses and provide broad spectrum immunogenicity. J. Mol. Recognit. 6, 81\u201394. https:\/\/doi.org\/10.1002\/jmr.300060206 (1993).","journal-title":"J. Mol. Recognit."},{"key":"1549_CR22","doi-asserted-by":"publisher","first-page":"4420","DOI":"10.1016\/j.vaccine.2014.06.060","volume":"32","author":"X Wen","year":"2014","unstructured":"Wen, X. et al. Inclusion of a universal tetanus toxoid CD4(+) T cell epitope P2 significantly enhanced the immunogenicity of recombinant rotavirus DeltaVP8* subunit parenteral vaccines. Vaccine 32, 4420\u20134427. https:\/\/doi.org\/10.1016\/j.vaccine.2014.06.060 (2014).","journal-title":"Vaccine"},{"key":"1549_CR23","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1128\/JVI.01835-10","volume":"85","author":"M Tan","year":"2011","unstructured":"Tan, M. et al. Norovirus P particle, a novel platform for vaccine development and antibody production. J. Virol. 85, 753\u2013764. https:\/\/doi.org\/10.1128\/JVI.01835-10 (2011).","journal-title":"J. Virol."},{"key":"1549_CR24","doi-asserted-by":"publisher","first-page":"10665","DOI":"10.1021\/acsnano.8b02776","volume":"12","author":"M Xia","year":"2018","unstructured":"Xia, M. et al. Bioengineered norovirus S60 nanoparticles as a multifunctional vaccine platform. ACS Nano 12, 10665\u201310682. https:\/\/doi.org\/10.1021\/acsnano.8b02776 (2018).","journal-title":"ACS Nano"},{"key":"1549_CR25","doi-asserted-by":"publisher","first-page":"3286","DOI":"10.1016\/j.vaccine.2017.04.078","volume":"35","author":"M Broker","year":"2017","unstructured":"Broker, M., Berti, F., Schneider, J. & Vojtek, I. Polysaccharide conjugate vaccine protein carriers as a \u201cneglected valency\u201d\u2014Potential and limitations. Vaccine 35, 3286\u20133294. https:\/\/doi.org\/10.1016\/j.vaccine.2017.04.078 (2017).","journal-title":"Vaccine"},{"key":"1549_CR26","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1038\/nm.2535","volume":"17","author":"FY Avci","year":"2011","unstructured":"Avci, F. Y., Li, X., Tsuji, M. & Kasper, D. L. A mechanism for glycoconjugate vaccine activation of the adaptive immune system and its implications for vaccine design. Nat. Med. 17, 1602\u20131609. https:\/\/doi.org\/10.1038\/nm.2535 (2011).","journal-title":"Nat. Med."},{"key":"1549_CR27","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1517\/17460441.2011.609554","volume":"6","author":"P Costantino","year":"2011","unstructured":"Costantino, P., Rappuoli, R. & Berti, F. The design of semi-synthetic and synthetic glycoconjugate vaccines. Expert Opin. Drug Discov. 6, 1045\u20131066. https:\/\/doi.org\/10.1517\/17460441.2011.609554 (2011).","journal-title":"Expert Opin. Drug Discov."},{"key":"1549_CR28","doi-asserted-by":"publisher","first-page":"2978","DOI":"10.1016\/j.vaccine.2018.04.035","volume":"36","author":"SJ An","year":"2018","unstructured":"An, S. J. et al. Development of a bivalent conjugate vaccine candidate against malaria transmission and typhoid fever. Vaccine 36, 2978\u20132984. https:\/\/doi.org\/10.1016\/j.vaccine.2018.04.035 (2018).","journal-title":"Vaccine"},{"key":"1549_CR29","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.4161\/hv.29054","volume":"10","author":"CA MacLennan","year":"2014","unstructured":"MacLennan, C. A., Martin, L. B. & Micoli, F. Vaccines against invasive Salmonella disease: current status and future directions. Hum. Vaccin. Immunother. 10, 1478\u20131493. https:\/\/doi.org\/10.4161\/hv.29054 (2014).","journal-title":"Hum. Vaccin. Immunother."},{"key":"1549_CR30","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/S0140-6736(13)62708-7","volume":"385","author":"J Wain","year":"2015","unstructured":"Wain, J., Hendriksen, R. S., Mikoleit, M. L., Keddy, K. H. & Ochiai, R. L. Typhoid fever. Lancet 385, 1136\u20131145. https:\/\/doi.org\/10.1016\/S0140-6736(13)62708-7 (2015).","journal-title":"Lancet"},{"key":"1549_CR31","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S1473-3099(13)70241-X","volume":"14","author":"ZA Bhutta","year":"2014","unstructured":"Bhutta, Z. A. et al. Immunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia: results from two randomised, observer-blind, age de-escalation, phase 2 trials. Lancet Infect. Dis. 14, 119\u2013129. https:\/\/doi.org\/10.1016\/S1473-3099(13)70241-X (2014).","journal-title":"Lancet Infect. Dis."},{"key":"1549_CR32","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/j.vaccine.2011.12.046","volume":"30","author":"SJ An","year":"2012","unstructured":"An, S. J. et al. Immune suppression induced by Vi capsular polysaccharide is overcome by Vi-DT conjugate vaccine. Vaccine 30, 1023\u20131028. https:\/\/doi.org\/10.1016\/j.vaccine.2011.12.046 (2012).","journal-title":"Vaccine"},{"key":"1549_CR33","doi-asserted-by":"publisher","DOI":"10.1128\/mSphere.00520-19","author":"F Avci","year":"2019","unstructured":"Avci, F. et al. Glycoconjugates: what it would take to master these well-known yet little-understood immunogens for vaccine development. MSphere https:\/\/doi.org\/10.1128\/mSphere.00520-19 (2019).","journal-title":"MSphere"},{"key":"1549_CR34","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1016\/j.vaccine.2009.01.005","volume":"27","author":"EM Pollabauer","year":"2009","unstructured":"Pollabauer, E. M., Petermann, R. & Ehrlich, H. J. The influence of carrier protein on the immunogenicity of simultaneously administered conjugate vaccines in infants. Vaccine 27, 1674\u20131679. https:\/\/doi.org\/10.1016\/j.vaccine.2009.01.005 (2009).","journal-title":"Vaccine"},{"key":"1549_CR35","doi-asserted-by":"publisher","first-page":"4235","DOI":"10.1016\/j.vaccine.2016.06.039","volume":"34","author":"M Tontini","year":"2016","unstructured":"Tontini, M. et al. Preclinical studies on new proteins as carrier for glycoconjugate vaccines. Vaccine 34, 4235\u20134242. https:\/\/doi.org\/10.1016\/j.vaccine.2016.06.039 (2016).","journal-title":"Vaccine"},{"key":"1549_CR36","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.meegid.2017.08.019","volume":"55","author":"MA Rojas","year":"2017","unstructured":"Rojas, M. A., Goncalves, J. L. S., Dias, H. G., Manchego, A. & Santos, N. Identification of two novel rotavirus A genotypes, G35 and P[50], from Peruvian alpaca faeces. Infect. Genet. Evol. 55, 71\u201374. https:\/\/doi.org\/10.1016\/j.meegid.2017.08.019 (2017).","journal-title":"Infect. Genet. Evol."},{"key":"1549_CR37","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/rmv.448","volume":"15","author":"N Santos","year":"2005","unstructured":"Santos, N. & Hoshino, Y. Global distribution of rotavirus serotypes\/genotypes and its implication for the development and implementation of an effective rotavirus vaccine. Rev. Med. Virol. 15, 29\u201356. https:\/\/doi.org\/10.1002\/rmv.448 (2005).","journal-title":"Rev. Med. Virol."},{"key":"1549_CR38","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3923\/pjbs.2017.59.69","volume":"20","author":"D Ouermi","year":"2017","unstructured":"Ouermi, D. et al. Molecular epidemiology of rotavirus in children under five in Africa (2006\u20132016): A systematic review. Pak. J. Biol. Sci. 20, 59\u201369. https:\/\/doi.org\/10.3923\/pjbs.2017.59.69 (2017).","journal-title":"Pak. J. Biol. Sci."},{"key":"1549_CR39","doi-asserted-by":"publisher","first-page":"7618","DOI":"10.1016\/j.vaccine.2011.08.019","volume":"29","author":"SJ An","year":"2011","unstructured":"An, S. J. et al. Physico-chemical properties of Salmonella typhi Vi polysaccharide-diphtheria toxoid conjugate vaccines affect immunogenicity. Vaccine 29, 7618\u20137623. https:\/\/doi.org\/10.1016\/j.vaccine.2011.08.019 (2011).","journal-title":"Vaccine"},{"key":"1549_CR40","doi-asserted-by":"publisher","first-page":"5755","DOI":"10.1016\/j.vaccine.2014.08.041","volume":"32","author":"N Kothari","year":"2014","unstructured":"Kothari, N. et al. Preparation and testing of a Vi conjugate vaccine using pneumococcal surface protein A (PspA) from Streptococcus pneumoniae as the carrier protein. Vaccine 32, 5755\u20135760. https:\/\/doi.org\/10.1016\/j.vaccine.2014.08.041 (2014).","journal-title":"Vaccine"},{"key":"1549_CR41","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1016\/j.vaccine.2015.03.068","volume":"33","author":"M Xue","year":"2015","unstructured":"Xue, M. et al. Characterization and protective efficacy in an animal model of a novel truncated rotavirus VP8 subunit parenteral vaccine candidate. Vaccine 33, 2606\u20132613. https:\/\/doi.org\/10.1016\/j.vaccine.2015.03.068 (2015).","journal-title":"Vaccine"},{"key":"1549_CR42","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1073\/pnas.1819612116","volume":"116","author":"R Rappuoli","year":"2019","unstructured":"Rappuoli, R., De Gregorio, E. & Costantino, P. On the mechanisms of conjugate vaccines. Proc. Natl. Acad. Sci. U.S.A. 116, 14\u201316. https:\/\/doi.org\/10.1073\/pnas.1819612116 (2019).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"1549_CR43","doi-asserted-by":"publisher","first-page":"E1143","DOI":"10.1073\/pnas.1425005112","volume":"112","author":"A Thanawastien","year":"2015","unstructured":"Thanawastien, A., Cartee, R. T., Griffin, T. J. & t., Killeen, K. P. & Mekalanos, J. J.,. Conjugate-like immunogens produced as protein capsular matrix vaccines. Proc. Natl. Acad. Sci. U.S.A. 112, E1143-1151. https:\/\/doi.org\/10.1073\/pnas.1425005112 (2015).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"1549_CR44","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1084\/jem.50.4.521","volume":"50","author":"WF Goebel","year":"1929","unstructured":"Goebel, W. F. & Avery, O. T. chemo-immunological studies on conjugated carbohydrate-proteins: I. The synthesis of p-aminophenol beta-glucoside, p-aminophenol beta-galactoside, and their coupling with serum globulin. J. Exp. Med. 50, 521\u2013531. https:\/\/doi.org\/10.1084\/jem.50.4.521 (1929).","journal-title":"J. Exp. Med."},{"key":"1549_CR45","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1084\/jem.50.4.533","volume":"50","author":"OT Avery","year":"1929","unstructured":"Avery, O. T. & Goebel, W. F. Chemo-immunological studies on conjugated carbohydrate-proteins: Ii. immunological specificity of synthetic sugar-protein antigens. J. Exp. Med. 50, 533\u2013550. https:\/\/doi.org\/10.1084\/jem.50.4.533 (1929).","journal-title":"J. Exp. Med."},{"key":"1549_CR46","unstructured":"Agency, E. M. EMEA Assessment report for Synflorix, 2009)."},{"key":"1549_CR47","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1016\/j.vaccine.2015.01.061","volume":"33","author":"SJ An","year":"2015","unstructured":"An, S. J., Woo, J. S., Chae, M. H., Kothari, S. & Carbis, R. Preparation and testing of a Haemophilus influenzae Type b\/Hepatitis B surface antigen conjugate vaccine. Vaccine 33, 1614\u20131619. https:\/\/doi.org\/10.1016\/j.vaccine.2015.01.061 (2015).","journal-title":"Vaccine"},{"key":"1549_CR48","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1128\/CVI.00266-09","volume":"17","author":"C Cui","year":"2010","unstructured":"Cui, C. et al. Physical and chemical characterization and immunologic properties of Salmonella enterica serovar typhi capsular polysaccharide-diphtheria toxoid conjugates. Clin. Vaccine Immunol. 17, 73\u201379. https:\/\/doi.org\/10.1128\/CVI.00266-09 (2010).","journal-title":"Clin. Vaccine Immunol."},{"key":"1549_CR49","doi-asserted-by":"publisher","first-page":"24443","DOI":"10.1073\/pnas.2005857117","volume":"117","author":"F Micoli","year":"2020","unstructured":"Micoli, F. et al. Short Vi-polysaccharide abrogates T-independent immune response and hyporesponsiveness elicited by long Vi-CRM197 conjugate vaccine. Proc. Natl. Acad. Sci. U.S.A. 117, 24443\u201324449. https:\/\/doi.org\/10.1073\/pnas.2005857117 (2020).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"1549_CR50","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0189100","volume":"12","author":"M Arcuri","year":"2017","unstructured":"Arcuri, M. et al. The influence of conjugation variables on the design and immunogenicity of a glycoconjugate vaccine against Salmonella Typhi. PLoS ONE 12, e0189100. https:\/\/doi.org\/10.1371\/journal.pone.0189100 (2017).","journal-title":"PLoS ONE"},{"key":"1549_CR51","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0025398","volume":"6","author":"P van Damme","year":"2011","unstructured":"van Damme, P. et al. Safety, immunogenicity and dose ranging of a new Vi-CRM(1)(9)(7) conjugate vaccine against typhoid fever: randomized clinical testing in healthy adults. PLoS ONE 6, e25398. https:\/\/doi.org\/10.1371\/journal.pone.0025398 (2011).","journal-title":"PLoS ONE"},{"key":"1549_CR52","doi-asserted-by":"publisher","first-page":"57","DOI":"10.4049\/jimmunol.1100783","volume":"188","author":"JB Foote","year":"2012","unstructured":"Foote, J. B., Mahmoud, T. I., Vale, A. M. & Kearney, J. F. Long-term maintenance of polysaccharide-specific antibodies by IgM-secreting cells. J. Immunol. 188, 57\u201367. https:\/\/doi.org\/10.4049\/jimmunol.1100783 (2012).","journal-title":"J. Immunol."},{"key":"1549_CR53","doi-asserted-by":"publisher","first-page":"817","DOI":"10.3389\/fimmu.2017.00817","volume":"8","author":"M van der Heiden","year":"2017","unstructured":"van der Heiden, M. et al. Novel intervention in the aging population: A primary meningococcal vaccine inducing protective IgM responses in middle-aged adults. Front. Immunol. 8, 817. https:\/\/doi.org\/10.3389\/fimmu.2017.00817 (2017).","journal-title":"Front. Immunol."},{"key":"1549_CR54","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1016\/j.vaccine.2014.02.050","volume":"32","author":"SC Szu","year":"2014","unstructured":"Szu, S. C., Klugman, K. P. & Hunt, S. Re-examination of immune response and estimation of anti-Vi IgG protective threshold against typhoid fever-based on the efficacy trial of Vi conjugate in young children. Vaccine 32, 2359\u20132363. https:\/\/doi.org\/10.1016\/j.vaccine.2014.02.050 (2014).","journal-title":"Vaccine"},{"key":"1549_CR55","doi-asserted-by":"publisher","first-page":"3188","DOI":"10.1128\/IAI.05081-11","volume":"79","author":"JC Lindow","year":"2011","unstructured":"Lindow, J. C., Fimlaid, K. A., Bunn, J. Y. & Kirkpatrick, B. D. Antibodies in action: Role of human opsonins in killing Salmonella enterica serovar Typhi. Infect. Immun. 79, 3188\u20133194. https:\/\/doi.org\/10.1128\/IAI.05081-11 (2011).","journal-title":"Infect. Immun."},{"key":"1549_CR56","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1128\/CVI.00245-09","volume":"16","author":"AS Pulickal","year":"2009","unstructured":"Pulickal, A. S. et al. Kinetics of the natural, humoral immune response to Salmonella enterica serovar Typhi in Kathmandu Nepal. Clin. Vaccine Immunol. 16, 1413\u20131419. https:\/\/doi.org\/10.1128\/CVI.00245-09 (2009).","journal-title":"Clin. Vaccine Immunol."},{"key":"1549_CR57","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1099\/jmm.0.047159-0","volume":"62","author":"H Ahmadi","year":"2013","unstructured":"Ahmadi, H. et al. Immunological evaluation of Vi capsular polysaccharide of Salmonella enterica subsp. Typhi vaccine by serum bactericidal assay. J. Med. Microbiol. 62, 283\u2013286. https:\/\/doi.org\/10.1099\/jmm.0.047159-0 (2013).","journal-title":"J. Med. Microbiol."},{"key":"1549_CR58","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aat4615","author":"R Rappuoli","year":"2018","unstructured":"Rappuoli, R. Glycoconjugate vaccines: Principles and mechanisms. Sci. Transl. Med. https:\/\/doi.org\/10.1126\/scitranslmed.aat4615 (2018).","journal-title":"Sci. Transl. Med."},{"key":"1549_CR59","doi-asserted-by":"publisher","first-page":"325","DOI":"10.2174\/1568005014605964","volume":"1","author":"GB Lesinski","year":"2001","unstructured":"Lesinski, G. B. & Westerink, M. A. Vaccines against polysaccharide antigens. Curr. Drug Targets Infect. Disord. 1, 325\u2013334. https:\/\/doi.org\/10.2174\/1568005014605964 (2001).","journal-title":"Curr. Drug Targets Infect. Disord."},{"key":"1549_CR60","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1586\/erv.11.8","volume":"10","author":"J Poolman","year":"2011","unstructured":"Poolman, J. & Borrow, R. Hyporesponsiveness and its clinical implications after vaccination with polysaccharide or glycoconjugate vaccines. Expert Rev. Vaccines 10, 307\u2013322. https:\/\/doi.org\/10.1586\/erv.11.8 (2011).","journal-title":"Expert Rev. Vaccines"},{"key":"1549_CR61","doi-asserted-by":"publisher","DOI":"10.3390\/antib9040053","author":"BA Keyt","year":"2020","unstructured":"Keyt, B. A., Baliga, R., Sinclair, A. M., Carroll, S. F. & Peterson, M. S. Structure, function, and therapeutic use of IgM antibodies. Antibodies https:\/\/doi.org\/10.3390\/antib9040053 (2020).","journal-title":"Antibodies"},{"key":"1549_CR62","doi-asserted-by":"publisher","first-page":"4078","DOI":"10.4049\/jimmunol.1701348","volume":"200","author":"KD Pandya","year":"2018","unstructured":"Pandya, K. D. et al. An unmutated IgM response to the Vi polysaccharide of Salmonella Typhi contributes to protective immunity in a murine model of typhoid. J. Immunol. 200, 4078\u20134084. https:\/\/doi.org\/10.4049\/jimmunol.1701348 (2018).","journal-title":"J. Immunol."},{"key":"1549_CR63","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00211-18","author":"V Belde","year":"2018","unstructured":"Belde, V. et al. Terminal deoxynucleotidyl transferase is not required for antibody response to polysaccharide vaccines against streptococcus pneumoniae and Salmonella enterica Serovar Typhi. Infect. Immun. https:\/\/doi.org\/10.1128\/IAI.00211-18 (2018).","journal-title":"Infect. Immun."},{"key":"1549_CR64","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.micpath.2016.05.013","volume":"97","author":"MS Jang","year":"2016","unstructured":"Jang, M. S., Sahastrabuddhe, S., Yun, C. H., Han, S. H. & Yang, J. S. Serum bactericidal assay for the evaluation of typhoid vaccine using a semi-automated colony-counting method. Microb. Pathog. 97, 19\u201326. https:\/\/doi.org\/10.1016\/j.micpath.2016.05.013 (2016).","journal-title":"Microb. Pathog."},{"key":"1549_CR65","doi-asserted-by":"publisher","first-page":"7268","DOI":"10.1073\/pnas.0502437102","volume":"102","author":"LE Westerman","year":"2005","unstructured":"Westerman, L. E., McClure, H. M., Jiang, B., Almond, J. W. & Glass, R. I. Serum IgG mediates mucosal immunity against rotavirus infection. Proc. Natl. Acad. Sci. U.S.A. 102, 7268\u20137273. https:\/\/doi.org\/10.1073\/pnas.0502437102 (2005).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"1549_CR66","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines8030462","author":"JW Ecker","year":"2020","unstructured":"Ecker, J. W. et al. High-yield expression and purification of recombinant influenza virus proteins from stably-transfected mammalian cell lines. vaccines https:\/\/doi.org\/10.3390\/vaccines8030462 (2020).","journal-title":"vaccines"},{"key":"1549_CR67","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.tibtech.2005.03.012","volume":"23","author":"DS Waugh","year":"2005","unstructured":"Waugh, D. S. Making the most of affinity tags. Trends Biotechnol. 23, 316\u2013320. https:\/\/doi.org\/10.1016\/j.tibtech.2005.03.012 (2005).","journal-title":"Trends Biotechnol."},{"key":"1549_CR68","doi-asserted-by":"publisher","first-page":"7339","DOI":"10.1128\/JVI.75.16.7339-7350.2001","volume":"75","author":"PR Dormitzer","year":"2001","unstructured":"Dormitzer, P. R., Greenberg, H. B. & Harrison, S. C. Proteolysis of monomeric recombinant rotavirus VP4 yields an oligomeric VP5* core. J. Virol. 75, 7339\u20137350. https:\/\/doi.org\/10.1128\/JVI.75.16.7339-7350.2001 (2001).","journal-title":"J. Virol."},{"key":"1549_CR69","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1016\/s0140-6736(96)06392-1","volume":"349","author":"R Booy","year":"1997","unstructured":"Booy, R., Heath, P. T., Slack, M. P., Begg, N. & Moxon, E. R. Vaccine failures after primary immunisation with Haemophilus influenzae type-b conjugate vaccine without booster. Lancet 349, 1197\u20131202. https:\/\/doi.org\/10.1016\/s0140-6736(96)06392-1 (1997).","journal-title":"Lancet"},{"key":"1549_CR70","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/s0022-3476(95)70545-7","volume":"126","author":"JM Lieberman","year":"1995","unstructured":"Lieberman, J. M. et al. Effect of neonatal immunization with diphtheria and tetanus toxoids on antibody responses to Haemophilus influenzae type b conjugate vaccines. J. Pediatr. 126, 198\u2013205. https:\/\/doi.org\/10.1016\/s0022-3476(95)70545-7 (1995).","journal-title":"J. Pediatr."},{"key":"1549_CR71","doi-asserted-by":"publisher","first-page":"5513","DOI":"10.1016\/j.vaccine.2010.06.026","volume":"28","author":"R Dagan","year":"2010","unstructured":"Dagan, R., Poolman, J. & Siegrist, C. A. Glycoconjugate vaccines and immune interference: A review. Vaccine 28, 5513\u20135523. https:\/\/doi.org\/10.1016\/j.vaccine.2010.06.026 (2010).","journal-title":"Vaccine"},{"key":"1549_CR72","doi-asserted-by":"publisher","DOI":"10.3390\/molecules23061451","author":"F Micoli","year":"2018","unstructured":"Micoli, F., Adamo, R. & Costantino, P. Protein carriers for glycoconjugate vaccines: History, selection criteria characterization and new trends. Molecules https:\/\/doi.org\/10.3390\/molecules23061451 (2018).","journal-title":"Molecules"},{"key":"1549_CR73","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1128\/IAI.66.5.2093-2098.1998","volume":"66","author":"R Dagan","year":"1998","unstructured":"Dagan, R., Eskola, J., Leclerc, C. & Leroy, O. Reduced response to multiple vaccines sharing common protein epitopes that are administered simultaneously to infants. Infect. Immun. 66, 2093\u20132098. https:\/\/doi.org\/10.1128\/IAI.66.5.2093-2098.1998 (1998).","journal-title":"Infect. Immun."},{"key":"1549_CR74","doi-asserted-by":"publisher","first-page":"15","DOI":"10.4161\/hv.5.1.6520","volume":"5","author":"HJ Boot","year":"2009","unstructured":"Boot, H. J. & Schipper, C. M. Simultaneous vaccination with Prevenar and multicomponent vaccines for children: Interference or no interference?. Hum. Vaccin. 5, 15\u201317. https:\/\/doi.org\/10.4161\/hv.5.1.6520 (2009).","journal-title":"Hum. Vaccin."},{"key":"1549_CR75","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1016\/j.vaccine.2013.02.006","volume":"31","author":"SC Szu","year":"2013","unstructured":"Szu, S. C. et al. A human IgG anti-Vi reference for Salmonella typhi with weight-based antibody units assigned. Vaccine 31, 1970\u20131974. https:\/\/doi.org\/10.1016\/j.vaccine.2013.02.006 (2013).","journal-title":"Vaccine"},{"key":"1549_CR76","doi-asserted-by":"publisher","first-page":"3678","DOI":"10.1128\/IAI.61.9.3678-3687.1993","volume":"61","author":"DN Taylor","year":"1993","unstructured":"Taylor, D. N. et al. Synthesis, characterization, and clinical evaluation of conjugate vaccines composed of the O-specific polysaccharides of Shigella dysenteriae type 1, Shigella flexneri type 2a, and Shigella sonnei (Plesiomonas shigelloides) bound to bacterial toxoids. Infect. Immun. 61, 3678\u20133687. https:\/\/doi.org\/10.1128\/IAI.61.9.3678-3687.1993 (1993).","journal-title":"Infect. Immun."},{"key":"1549_CR77","doi-asserted-by":"publisher","first-page":"4884","DOI":"10.1128\/IAI.72.8.4884-4887.2004","volume":"72","author":"K Baraldo","year":"2004","unstructured":"Baraldo, K. et al. N19 polyepitope as a carrier for enhanced immunogenicity and protective efficacy of meningococcal conjugate vaccines. Infect. Immun. 72, 4884\u20134887. https:\/\/doi.org\/10.1128\/IAI.72.8.4884-4887.2004 (2004).","journal-title":"Infect. Immun."},{"key":"1549_CR78","doi-asserted-by":"publisher","first-page":"5835","DOI":"10.1128\/IAI.73.9.5835-5841.2005","volume":"73","author":"K Baraldo","year":"2005","unstructured":"Baraldo, K. et al. Combined conjugate vaccines: enhanced immunogenicity with the N19 polyepitope as a carrier protein. Infect. Immun. 73, 5835\u20135841. https:\/\/doi.org\/10.1128\/IAI.73.9.5835-5841.2005 (2005).","journal-title":"Infect. Immun."},{"key":"1549_CR79","doi-asserted-by":"publisher","first-page":"3839","DOI":"10.1172\/JCI128382","volume":"130","author":"N Feng","year":"2019","unstructured":"Feng, N. et al. Human VP8* mAbs neutralize rotavirus selectively in human intestinal epithelial cells. J. Clin. Invest. 130, 3839\u20133851. https:\/\/doi.org\/10.1172\/JCI128382 (2019).","journal-title":"J. Clin. Invest."},{"key":"1549_CR80","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aam5434","author":"N Nair","year":"2017","unstructured":"Nair, N. et al. VP4- and VP7-specific antibodies mediate heterotypic immunity to rotavirus in humans. Sci. Transl. Med. https:\/\/doi.org\/10.1126\/scitranslmed.aam5434 (2017).","journal-title":"Sci. Transl. Med."},{"key":"1549_CR81","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1128\/CVI.00532-10","volume":"18","author":"VD Thiem","year":"2011","unstructured":"Thiem, V. D. et al. The Vi conjugate typhoid vaccine is safe, elicits protective levels of IgG anti-Vi, and is compatible with routine infant vaccines. Clin. Vaccine Immunol. 18, 730\u2013735. https:\/\/doi.org\/10.1128\/CVI.00532-10 (2011).","journal-title":"Clin. Vaccine Immunol."},{"key":"1549_CR82","doi-asserted-by":"publisher","first-page":"223","DOI":"10.4269\/ajtmh.12-0743","volume":"89","author":"F Ferdous","year":"2013","unstructured":"Ferdous, F. et al. Severity of diarrhea and malnutrition among under five-year-old children in rural Bangladesh. Am. J. Trop. Med. Hyg. 89, 223\u2013228. https:\/\/doi.org\/10.4269\/ajtmh.12-0743 (2013).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"1549_CR83","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1172\/JCI34005","volume":"118","author":"WA Petri Jr","year":"2008","unstructured":"Petri, W. A. Jr. et al. Enteric infections, diarrhea, and their impact on function and development. J. Clin. Invest. 118, 1277\u20131290. https:\/\/doi.org\/10.1172\/JCI34005 (2008).","journal-title":"J. Clin. Invest."},{"key":"1549_CR84","doi-asserted-by":"publisher","first-page":"5937","DOI":"10.1016\/j.vaccine.2015.09.017","volume":"33","author":"LH Lua","year":"2015","unstructured":"Lua, L. H., Fan, Y., Chang, C., Connors, N. K. & Middelberg, A. P. Synthetic biology design to display an 18 kDa rotavirus large antigen on a modular virus-like particle. Vaccine 33, 5937\u20135944. https:\/\/doi.org\/10.1016\/j.vaccine.2015.09.017 (2015).","journal-title":"Vaccine"},{"key":"1549_CR85","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines7040177","author":"A Ramesh","year":"2019","unstructured":"Ramesh, A. et al. Parenterally administered P24-VP8* nanoparticle vaccine conferred strong protection against rotavirus diarrhea and virus shedding in gnotobiotic pigs. Vaccines https:\/\/doi.org\/10.3390\/vaccines7040177 (2019).","journal-title":"Vaccines"},{"key":"1549_CR86","doi-asserted-by":"publisher","DOI":"10.3390\/v13010072","author":"M Xia","year":"2021","unstructured":"Xia, M., Huang, P., Jiang, X. & Tan, M. A nanoparticle-based trivalent vaccine targeting the glycan binding VP8* domains of rotaviruses. Viruses https:\/\/doi.org\/10.3390\/v13010072 (2021).","journal-title":"Viruses"},{"key":"1549_CR87","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/S1473-3099(17)30242-6","volume":"17","author":"MJ Groome","year":"2017","unstructured":"Groome, M. J. et al. Safety and immunogenicity of a parenteral P2-VP8-P[8] subunit rotavirus vaccine in toddlers and infants in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet Infect. Dis. 17, 843\u2013853. https:\/\/doi.org\/10.1016\/S1473-3099(17)30242-6 (2017).","journal-title":"Lancet Infect. Dis."},{"key":"1549_CR88","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41541-018-0089-x","volume":"3","author":"H HogenEsch","year":"2018","unstructured":"HogenEsch, H., O\u2019Hagan, D. T. & Fox, C. B. Optimizing the utilization of aluminum adjuvants in vaccines: you might just get what you want. NPJ Vaccines 3, 51. https:\/\/doi.org\/10.1038\/s41541-018-0089-x (2018).","journal-title":"NPJ Vaccines"},{"key":"1549_CR89","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1128\/iai.65.6.2088-2093.1997","volume":"65","author":"Z Kossaczka","year":"1997","unstructured":"Kossaczka, Z. et al. Synthesis and immunological properties of Vi and di-O-acetyl pectin protein conjugates with adipic acid dihydrazide as the linker. Infect. Immun. 65, 2088\u20132093. https:\/\/doi.org\/10.1128\/iai.65.6.2088-2093.1997 (1997).","journal-title":"Infect. Immun."},{"key":"1549_CR90","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.1000412","volume":"8","author":"C Kilkenny","year":"2010","unstructured":"Kilkenny, C., Browne, W. J., Cuthill, I. C., Emerson, M. & Altman, D. G. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol. 8, e1000412. https:\/\/doi.org\/10.1371\/journal.pbio.1000412 (2010).","journal-title":"PLoS Biol."},{"key":"1549_CR91","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1093\/infdis\/149.5.694","volume":"149","author":"Y Hoshino","year":"1984","unstructured":"Hoshino, Y., Wyatt, R. G., Greenberg, H. B., Flores, J. & Kapikian, A. Z. Serotypic similarity and diversity of rotaviruses of mammalian and avian origin as studied by plaque-reduction neutralization. J. Infect. Dis. 149, 694\u2013702. https:\/\/doi.org\/10.1093\/infdis\/149.5.694 (1984).","journal-title":"J. Infect. Dis."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-01549-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-01549-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-01549-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T17:22:24Z","timestamp":1670088144000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-01549-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,11]]},"references-count":91,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["1549"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-01549-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,11]]},"assertion":[{"value":"27 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22037"}}